Agile Therapeutics Inc (NASDAQ:AGRX) – Analysts at Cantor Fitzgerald raised their FY2017 earnings estimates for Agile Therapeutics in a report released on Tuesday, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Russo now anticipates that the specialty pharmaceutical company will earn ($1.18) per share for the year, up from their prior forecast of ($1.42). Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Wednesday, March 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.01. ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Agile Therapeutics Inc Raised by Cantor Fitzgerald (AGRX)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/04/21/agile-therapeutics-inc-agrx-forecasted-to-earn-fy2017-earnings-of-1-18-per-share-updated-updated.html.
AGRX has been the topic of several other reports. Royal Bank of Canada set a $8.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research note on Friday, January 27th. Janney Montgomery Scott reissued a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research note on Thursday, January 5th. Zacks Investment Research raised shares of Agile Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, March 7th. FBR & Co set a $10.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 11th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a research note on Monday, March 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $9.75.
Agile Therapeutics (NASDAQ:AGRX) traded down 0.66% on Thursday, hitting $3.03. 138,265 shares of the company traded hands. The firm’s market capitalization is $87.19 million. The stock’s 50-day moving average is $2.79 and its 200 day moving average is $4.61. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $8.65.
Several large investors have recently added to or reduced their stakes in AGRX. Perceptive Advisors LLC acquired a new stake in Agile Therapeutics during the fourth quarter valued at approximately $3,770,000. Deerfield Management Co. raised its position in Agile Therapeutics by 59.2% in the fourth quarter. Deerfield Management Co. now owns 398,000 shares of the specialty pharmaceutical company’s stock worth $2,269,000 after buying an additional 148,000 shares during the period. Highland Capital Management LP raised its position in Agile Therapeutics by 490.4% in the fourth quarter. Highland Capital Management LP now owns 142,724 shares of the specialty pharmaceutical company’s stock worth $813,000 after buying an additional 118,551 shares during the period. State Street Corp raised its position in Agile Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 142,442 shares of the specialty pharmaceutical company’s stock worth $811,000 after buying an additional 2,824 shares during the period. Finally, Renaissance Technologies LLC raised its position in Agile Therapeutics by 209.2% in the fourth quarter. Renaissance Technologies LLC now owns 64,000 shares of the specialty pharmaceutical company’s stock worth $365,000 after buying an additional 43,300 shares during the period. Institutional investors and hedge funds own 83.55% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Agile Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agile Therapeutics Inc and related companies.